Among three different isoforms, IDH1, IDH2 and IDH3, mutations in IDH1 or IDH2 occur in 20–30% of AML patients resulting in production of neomorphic enzymes, catalyzing abnormal DNA histone methylation and promoting leukemogenesis [96, 97]. Here, IDH1 is linked to acute myeloid leukemia.